The global human milk oligosaccharides (HMO) marketsize was valued at $125.9 million in 2020, and is estimated to reach $332.6 million by 2028, registering a CAGR of 14.1% from 2021 to 2028.
Human milk oligosaccharide (HMO) is a class of structurally complex, unconjugated glycans found in high concentrations in human milk. HMOs are minimally digested in the gastrointestinal system and reach the colon intact, where they shape the micro biota.
As HMOs are beneficial for immunity, several new techniques are being developed by key players in the Human Milk Oligosaccharides (HMO) market, such as isolating HMO from cow milk, employing costly techniques (chemically or enzymatically synthesizing), or utilizing microbes to produce them. Human Milk Oligosaccharides (HMO) market products are expensive, as a large amount of human milk is synthesized to produce a small amount of HMO. As a result, techniques for synthesis and extraction are improving with continuous research and development activities.
The functional benefits of these products have created a huge demand for biosynthetic production of HMOs for use as additives in infant formulas and other dietary products. HMO molecules can be produced chemically, through fermentation, or through enzymatic synthesis.
Moreover, surge in demand for HMOs has increased the utilization of various nutritional products used as food or dietary supplements. One of the major factors and Human Milk Oligosaccharides (HMO) market trends that boosts the Human Milk Oligosaccharides (HMO) market growth is the availability of new technologies such as enzymatic trans-glycosylation, which is used for artificially synthesizing the HMOs.
The Human Milk Oligosaccharides(HMO) market is expected to witness significant revenue generation during the forecast period, owing to increase in application scope in functional food & beverages and infant formula, rapid technological advancement in the product line, rise in health awareness, and rapid development of the dairy industry.
HMOs are important components of human milk that are available in a variety of concentrations and compositions. They are novel ingredients that require regulatory approval. In the U.S., HMOs are intended for use in food, as compared to dietary supplements, which are governed by Generally Recognized as Safe (GRAS). DuPont's CARE4U was GRAS-approved for use in infant formula and toddler foods in the U.S. With upsurge in demand for HMOs, two HMOs have undergone the novel food safety assessment in Europe, resulting in a positive evaluation outcome and approval by the European Commission.
HMOs have been used in infant formula and human milk for a prolonged period. The compositions, however, differ, and HMOs are not found in other foods. The path to Human Milk Oligosaccharides (HMO) market for new and novel HMOs as a dietary supplement is to have GRAS self-affirmed for use in food and sub sequently use it in the same form as a dietary supplement. 2'-O-fucosyllactose, 2'-fucosyllactose, and lacto-N-neotetraose have all received such notices.
Other major factors driving the demand for HMOs around the world include improvement in lifestyleand rise in concerns about health & wellness. Furthermore, HMOs in food supplements and functional food and beverage products can aid in the treatment of specific disorders and high-risk health conditions, which is acts as a key driving force of the global Human Milk Oligosaccharides (HMO) market. This has created Human Milk Oligosaccharides (HMO) market opportunity. However, high costs associated with the product is expected to pose a challenge for the growth of the market during Human Milk Oligosaccharides (HMO) market forecast.
By Type
2'FL segment is expected to grow at highest CAGR of 14.6% during the forecast period
HMOs are intrinsic components that can be used to manipulate the gut microbiota by providing an energy source for beneficial intestinal microbiota and potentially acting as decoy molecules to inactivate pathogens on mucosal surfaces, resulting in improved host health. Health-promoting oligosaccharides are in high demand, as the importance of the gut microbiota in human health has been revealed. The rules governing the implementation of HMOs differ depending on where a person lives. Different countries have different regulations governing novel foods and foods with health claims. The major regulatory requirements in the EU and the U.S. are similar, but the approval processes differ.
The COVID-19 pandemic had a significant impact on the Human Milk Oligosaccharides (HMO) market. The demand for HMO increased during the lockdown due to panic buying for at-home consumption during the initial phase of the pandemic. As a result, the sales of HMOs escalated during the pandemic, due to the fact that it serves as an immunity booster.
By Application
Infant Formula segment is expected to grow at highest CAGR of 14.5% during the forecast period.
The global Human Milk Oligosaccharides (HMO) market segmentation is done on the basis of type, application, distribution channel, and region. Depending on type, the market is categorized into 2’FL, 3’FL, 3’SL, and 6’SL.The applications covered in the market include infant formula, functional food & beverage, and food supplements. According to distribution channel, the market is fragmented into hypermarkets & supermarkets, drug store or pharmacy, mass merchandiser, departmental stores, mono-brand stores, specialty stores, and online sales channel. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In this way, Human Milk Oligosaccharides (HMO) market analysis is done.
By type, the 2’FLsegment garnered the highest market share in 2020, as 2'-fucosyllactose (2’FL) is well-known for its ability to protect against infectious diseases by preventing toxins and pathogens from adhering to epithelial cells. On the basis of application, the infant formula segment is anticipated to dominate the Human Milk Oligosaccharides (HMO) market share during the forecast period. This is attributed to beneficial properties offered by HMOs such as brain development and memory enhancement of infants.
By Distribution Channel
Drug Stores or Pharmacy segment is expected to grow at highest CAGR of 15.4% during the forecast period.
Depending on distribution channel, the drug store or pharmacy segment led the Human Milk Oligosaccharides (HMO) market in 2020. This is attributed to the fact that to attract and retain customers during the growing competition from mail-order retailers and supercenters, drug store operators have emphasized convenience factors such as extended store hours and drive-through locations. Region wise, Europe is expected to dominate the Human Milk Oligosaccharides (HMO) market, owing to increase in customer awareness in Europe about the health benefits of HMO in infant nutrition.
The prominent players operating in the Human Milk Oligosaccharides (HMO ) industry include Abbott Laboratories, BASF S.E., Biosynth Carbosynth, Chr. Hansen Holding A/S, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Elicityl S.A., Glycom A/S, Glycosyn, Inbiose NV, Medolac Laboratories, Neolacta Lifesciences Pvt. Ltd, Nestle Health Science, Royal DSM, and ZuChem.
By Regions
Europe dominates the market and is expected to grow at highest CAGR of 14.6% during the forecast period.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the current trends, estimations, and dynamics of the global Human Milk Oligosaccharides (HMO) market from 2021 to 2028 to identify the prevailing market opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier–buyer network.
- In-depth analysis of the market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- The market player positioning segment facilitates benchmarking while providing a clear understanding of the present position of the key market players.
- The report includes analysis of the regional as well as the global market, key players, market segments, application areas, and growth strategies.
Key Market Segments
By Type
- 2’FL
- 3’FL
- 3’SL
- 6’SL
By Application
- Infant Formula
- Functional Food & Beverage
- Food Supplements
By Distribution Channel
- Hypermarkets & Supermarkets
- Drug Store or Pharmacy
- Mass Merchandiser
- Departmental Stores
- Mono-brand Stores
- Specialty Stores
- Online Sales Channel
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- France
- Netherlands
- Germany
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- UAE
- Rest of LAMEA
Human Milk Oligosaccharides (HMO) Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | ROYAL DSM, Nestle Health Science, Medolac Laboratories, Dextra Laboratories Ltd, Biosynth Carbosynth, Inbiose NV, Glycosyn, DuPont Nutrition & Biosciences, Chr. Hansen Holding A/S, Elicityl S.A. |
Analyst Review
Human milk oligosaccharide (HMO) is a sugar found in human breast milk that is the third most abundant solid component after lactose and fats. It promotes vital health benefits related to immunity, digestion, and cognitive health. A number of factors are accelerating the growth of the HMO industry. The dairy industry's promising growth, surge in demand for food supplements, rise in demand for infant formula, and surge in health consciousness are the primary factors driving market growth.
HMOs have recently been recognized as an important component of food supplements and infant formulas. The FDA has studied infant formula supplemented with HMOs such as 2'fucosyllactose, lacto-N-neotetraose, and 2 oligosaccharides and recommended it as safe, well-tolerated, and supportive of age-appropriate growth in infants. Working mothers and mothers whose breast milk is deficient in HMOs can supplement their children's holistic development and nutritional needs by using infant formulas containing these unique oligosaccharides.
Abbott Healthcare's Similac infant nutrition formula contains 2'FL as one of its key ingredients. Many other applications of HMOs for adults have been identified. Glycom S/A, a Danish biotechnology company, for example, manufactures Holigos IBS to treat irritable bowel syndrome symptoms such as abdominal pain, constipation, diarrhea, and bloating. Many companies have taken advantage of the growing popularity of probiotics and their benefits for gut health to market dietary supplements containing HMO.
The global Human Milk Oligosaccharides (HMO) market size was valued at $125.9 million in 2020, and is estimated to reach $332.6 million by 2028, registering a CAGR of 14.1% from 2021 to 2028.
The CAGR of Human Milk Oligosaccharides (HMO) Market is 14.1% from 2021 to 2028.
The sample report of global Human Milk Oligosaccharides (HMO) market is available on Allied Market Research website on request.
The base year calculated in the Human Milk Oligosaccharides (HMO) market report is 2020.
The top companies in the global Human Milk Oligosaccharides (HMO) market are Abbott Laboratories, BASF S.E., Biosynth Carbosynth, Chr. Hansen Holding A/S, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Elicityl S.A., Glycom A/S, Glycosyn, Inbiose NV, Medolac Laboratories, Neolacta Lifesciences Pvt. Ltd, Nestle Health Science, Royal DSM and ZuChem.
The global Human Milk Oligosaccharides (HMO) market is segmented on the basis of type, application, distribution channel, and region. On the basis of type, the market is categorized into 2’FL, 3’FL, 3’SL, and 6’SL. As per application, it is divided into infant formula, functional food & beverage, and food supplements. According to distribution channel, the Human Milk Oligosaccharides (HMO) market is fragmented into hypermarkets & supermarkets, drug store or pharmacy, mass merchandiser, departmental stores, mono-brand stores, specialty stores, and online sales channel. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, France, the Netherlands, Germany, Turkey, and the rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the rest of Asia-Pacific), and LAMEA (Brazil, South Africa, the UAE, and the rest of LAMEA).
The key trends such as increased health consciousness among the consumers and surge in growth of food supplements will drive the Human Milk Oligosaccharides (HMO) market growth during the forecast period.
2’FL market holds the maximum market share of the Human Milk Oligosaccharides (HMO) market.
Due to COVID-19 pandemic, several brands have shifted their focus to e-commerce platforms to generate revenue and increase sales. Offline sales are increasing right now as government lockdown restrictions are gradually being lifted in a number of countries. This will have positive impact on Human Milk Oligosaccharides (HMO) Market in 2021.
Loading Table Of Content...
